Factor xa inhibitors

Intervention

1 paper4 findings

MeSH

  • 1 lab in 1 country
  • 4 of 4 findings with company ties
  • Humans1

Associations

4

Mortality

downin humans1HR 0.41

1 study
  1. Factor xa inhibitors lower the risk of mortality in humans (HR 0.41, 95% CI 0.23-0.75).

    “cardiovascular death were significantly lower in the Xa-I group than in the non-Xa-I group (hazard ratio [95% confidence interval]: 0.43 [0.30-0.61], 0.44 [0.29-0.66], 0.47 [0.22-1.04], and 0.41 [0.23-0.75]”

    Humansnonvalvular atrial fibrillation5-year

    Impact of Factor Xa inhibitors on cardiovascular events in older patients with nonvalvular atrial fibrillation

    Aging10 Apr 2025

Atherosclerosis

downin humans1HR 0.47

1 study
  1. Factor xa inhibitors lower the risk of atherosclerosis in humans (HR 0.47, 95% CI 0.22-1.04).

    “arteriosclerotic disease, and cardiovascular death were significantly lower in the Xa-I group than in the non-Xa-I group (hazard ratio [95% confidence interval]: 0.43 [0.30-0.61], 0.44 [0.29-0.66], 0.47 [0.22-1.04]”

    Humansnonvalvular atrial fibrillation5-year

    Impact of Factor Xa inhibitors on cardiovascular events in older patients with nonvalvular atrial fibrillation

    Aging10 Apr 2025

More on Atherosclerosis

Heart failure

downin humans1HR 0.44

1 study
  1. Factor xa inhibitors lower the risk of heart failure in humans (HR 0.44, 95% CI 0.29-0.66).

    “congestive heart failure, arteriosclerotic disease, and cardiovascular death were significantly lower in the Xa-I group than in the non-Xa-I group (hazard ratio [95% confidence interval]: 0.43 [0.30-0.61], 0.44 [0.29-0.66]”

    Humansnonvalvular atrial fibrillation5-year

    Impact of Factor Xa inhibitors on cardiovascular events in older patients with nonvalvular atrial fibrillation

    Aging10 Apr 2025

More on Heart failure

Cardiovascular events

downin humans1HR 0.43

1 study
  1. Factor xa inhibitors lower the risk of cardiovascular events in humans (HR 0.43, 95% CI 0.30-0.61).

    “The risks of cardiovascular events, congestive heart failure, arteriosclerotic disease, and cardiovascular death were significantly lower in the Xa-I group than in the non-Xa-I group”

    Humansnonvalvular atrial fibrillation5-year

    Impact of Factor Xa inhibitors on cardiovascular events in older patients with nonvalvular atrial fibrillation

    Aging10 Apr 2025

Latest